Bio Protocol
BIO - # 292 ActiveGobal Asset
-
Rating Score 68.72Rating Grade B
- Rating Version APYWA-v1.1 / Rating Date 2025-12-22
Overview
Bio Protocol is a layer designed for decentralized science (DeSci), enabling researchers, patients, and investors to fund biotechnology research and share research outcomes. The protocol supports the formation of BioDAOs—decentralized autonomous organizations for scientific research—aimed at addressing the limitations of traditional research funding models in areas such as rare diseases and longevity research. Bio Protocol also facilitates the management of tokenized intellectual property for BioDAOs and expands investor participation opportunities through its launchpad. BIO, the native asset of Bio Protocol, is used for participation in BioDAO research funding and governance voting.
Metric Radar Chart
Metric Bar Chart
Metric Trends
| Total Rating Score | TNNeutral |
|---|---|
| Market Accessibility | TNNeutral |
| Development Activity | TNNeutral |
| Market Liquidity | TL2Gradual Downtrend |
| Community Engagement | TNNeutral |
| Risk & Security | TNNeutral |
Total Rating Score Trend
Market Data
- Token Price $0.042186 (↘2.20%)
- Volume (24h) $16.83M (↘31.56%)
- Market Cap $79.79M (↗2.56%)
-
Circulating Supply
1,891,357,988 BIO
1,769,745,956 BIO
(Source : Coinmarketcap , Coingecko )
Listed Exchanges
- Korean
-
- Global
-
×
View All Exchanges
- Korean
-
- Global
-
Community Info
X (Twitter) Tweets (Last 30 Days)
297 (-23)
Development Info
-
GitHub Account
bio-xyz
-
Stars
98 (-)
- Commits (Last 3 Months) 773 (+4)
Security Audit Info
- Security Audit Status None
- CertiK Code Security Score 50 pts
(Source : Coinmarketcap , CertiK Skynet )
Issue Info
- Trading History
- 2025.10.20 [업비트] 거래소에 신규 거래 지원됩니다.
- 2025.08.19 [빗썸] 거래소에 신규 거래 지원됩니다.
- 2025.08.13 [코인원] 거래소에 신규 거래 지원됩니다.
- 2025.03.19 [코빗] 거래소에 신규 거래 지원되었습니다
- Risk History
- No records found
View Full History
| Category | Date | Exchange | Link | Grade | Details |
|---|---|---|---|---|---|
| Regular Evaluation | 2025-10-16 | - | - | B+(71.61) | [AW-0100-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-10-13 | - | - | B+(71.28) | [AW-0099-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-10-09 | - | - | B+(71.73) | [AW-0098-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-10-06 | - | - | B+(71.91) | [AW-0097-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-10-02 | - | - | B+(72.96) | [AW-0096-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-09-29 | - | - | B+(72.27) | [AW-0095-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-09-25 | - | - | B+(72.14) | [AW-0094-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-09-22 | - | - | B+(72.80) | [AW-0093-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-09-18 | - | - | B+(72.38) | [AW-0092-정기] 평가가 완료되었습니다. |
| Regular Evaluation | 2025-09-15 | - | - | B+(72.95) | [AW-0091-정기] 평가가 완료되었습니다. |
- Disclaimer
-
The ratings provided by APYWA (hereinafter 'the Company') are conducted via an automated system based on public data and are pure data-driven analysis results with no subjective elements. This rating material includes evaluations on five key metrics: Market Accessibility, Development Activity, Market Liquidity, Community Engagement, and Security. All information provided is for reference purposes only.
Our ratings are not intended as investment advice or recommendations, and we do not guarantee the accuracy, completeness, or timeliness of the information. Users must make their own investment decisions based on the provided data, and the Company bears no legal liability for any resulting losses or damages.
While the rating material is processed automatically based on reliable data, discrepancies with actual market conditions may occur due to data limitations. Therefore, the Company is not liable for any damages arising from the use of the provided information. All information contained herein is the property of the Company and may not be reproduced, distributed, or modified without prior approval.